japanese chewing tobacco Reviews | Japan Tobacco Big Tobacco Finds Surprise Allies

NCBI Bookshelf

(c) Identification of the Payment Amount Benchmark Period for a Part D Rebatable Drug No Longer Considered To Be a Selected Drug In proposed 428.202(c)(5), CMS proposes to codify policies described in section 40.2.2 of the revised Medicare Part D Drug Inflation Rebate Guidance relating to the identification of the payment amount benchmark period for a selected drug (as defined in section 1192(c) of the Act) with respect to a price applicability period (as defined in section 1191(b)(2) of the Act) in the case such Part D rebatable drug is no longer considered to be a selected drug

(1) Quality Performance Category in MVPs (a) Background on Population Health Administrative Claims-Based Measures In the CY 2021 PFS final rule, we discussed the inclusion of population health measures as a part of the foundational layer of MVPs, to improve patient outcomes, reduce reporting burden and costs, and better align with clinician quality improvement efforts (85 FR 84856 and 84857)

of this proposed rule for discussion on the burden estimates for these proposals